AOD-9604 in La Criba — Fat Loss Peptide Research Guide
AOD-9604 research guide for La Criba. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in La Criba searching for AOD-9604, the key fact to understand is that this compound is distributed via specialist online vendors. What this means for La Criba researchers is that geography is secondary to your ability to assess COA data — and those verification methods are available to every researcher. The core quality markers for AOD-9604 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. What follows is a vendor evaluation and quality guide built specifically around AOD-9604, covering everything a La Criba researcher needs to evaluate quality systematically.
What Studies Say About AOD-9604
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in La Criba studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Evaluate AOD-9604 Vendors
Quality AOD-9604 sourcing begins with a useful first test: does this vendor make batch-matched COAs available before purchase? Vendors who do are operating transparently. The HPLC chromatogram is the most important document in the COA: it should show a clear dominant peak representing AOD-9604, with minimal secondary peaks representing impurities — purity should be 98% or higher. For La Criba researchers evaluating new suppliers: a small initial order to verify quality before scaling up your order is standard practice in the community. Keep lyophilised AOD-9604 at −20°C until ready to use; reconstitute only the amount needed for the near-term protocol and return unused portion to the freezer.
Order AOD-9604 — ships to La Criba
COA-verified · International tracking · Research grade
All use of AOD-9604 in La Criba or anywhere must be research use only — this compound is not approved for human therapeutic use, and all handling should follow research laboratory protocols. Temperature excursions — even brief warming above recommended storage temperature — can cause partial degradation without detectable changes to appearance; always maintain cold chain and work with cold-shipped material. Endotoxin testing in the AOD-9604 COA is absolutely required — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at trace quantities, and no discount compensates for this missing data. PubMed and bioRxiv represent the most comprehensive research databases for AOD-9604 research; favour indexed journal publications over preprints over unreviewed preprints or forum reports.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
